Gyre Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Valuation Ratios
P/E Ratio85.93
P/S Ratio9.8217.34
P/B Ratio10.5525.07
Price/Tangible Book16.85
Price/FCF113.23
Price/OCF75.99
Enterprise Value Ratios
EV/Revenue9.9317.15
EV/EBITDA58.9695.72
EV/EBIT64.73101.27
EV/FCF111.98
Profitability & Returns
Return on Equity (ROE)0.20%-1.13%
Return on Assets (ROA)0.08%0.12%
Return on Invested Capital (ROIC)0.21%0.41%0.09%
Return on Capital Employed (ROCE)0.15%0.20%0.13%
Leverage & Solvency Ratios
Debt/Equity0.020.010.01
Debt/EBITDA0.090.020.06
Debt/FCF0.020.11
Liquidity Ratios
Current Ratio3.322.854.06
Quick Ratio2.642.493.33
Efficiency Ratios
Asset Turnover0.871.13
Inventory Turnover0.730.89
Yield & Distribution Ratios
Earnings Yield0.01%-0.05%
FCF Yield-0.01%0.01%
Buyback Yield-0.55%0.13%